BlissBio Goes Solo On HER2-Targeting ADC After Eisai Exit

New Results Ahead Of Planned IPO

 
• By Dexter Jie Yan
Bliss Biopharmaceutical is now on a solo quest to develop BB-1701, its HER2-targeting ADC. (Shutterstock)

More from Clinical Trials

More from R&D